Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference

Executive Summary

A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago

You may also be interested in...



Elan Insists Remaining Alzheimer's Portfolio Has Deep Roots And New Shoots

Now that Elan has sold its immunotherapy-based drug candidates for Alzheimer's disease to Johnson & Johnson, management says it wants to focus even more intensely on the remaining pipeline, including a series of early-stage drug candidates related to Alzheimer's

Elan Insists Remaining Alzheimer's Portfolio Has Deep Roots And New Shoots

Now that Elan has sold its immunotherapy-based drug candidates for Alzheimer's disease to Johnson & Johnson, management says it wants to focus even more intensely on the remaining pipeline, including a series of early-stage drug candidates related to Alzheimer's

Elan Insists Remaining Alzheimer's Portfolio Has Deep Roots And New Shoots

Now that Elan has sold its immunotherapy-based drug candidates for Alzheimer's disease to Johnson & Johnson, management says it wants to focus even more intensely on the remaining pipeline, including a series of early-stage drug candidates related to Alzheimer's

Related Content

UsernamePublicRestriction

Register

PS049933

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel